Correction of Insulin Resistance and Hyperandrogenism in Polycystic Ovary Syndrome By Combined Rosiglitazone and Clomiphene Citrate Therapy

Abstract

Objective: To investigate the effects of combined rosiglitazone and clomphene citrate versus clomiphene citrate monotherapy on serum insulin-like growth factor 1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3) levels in polycystic ovary syndrome (PCOS) and to evaluate these therapeutic interventions in the link between hyperinsulinemia and hormonal perturbations in PCOS.

Methods: We performed a randomized clinical study at the King Abul-Aziz and Cairo University Hospitals. We studied 50 women with PCOS. Clinical diagnosis was based on hyperandrogenism; hyperinsulinism; oligomenorrhea; or amenorrhea, anovulatory cycles, and ultrasonographic findings. They were randomly assigned to two groups of 25 women each. One group was treated with rosiglitazone and clomiphene citrate; the other was treated only with clomphene citrate. Serum concentrations of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, dehydroepiandrosterone sulfate (DHEAS), free testosterone, IGF-1, and IFGBP-3 were measured by specific radioimmunoassays before and after treatment.

Results: Combined rosiglitazone and clomphene treatment led to a significant reduction in area under the insulin curve (AUG insulin), whereas clomphene monotherapy did not lead to this reduction. Both types of treatment induced a significant decrease in LH, LH:FSH ratio, free testosterone, and IGF1:IGBP-3 ratio and were associated with a significant increase in IGFBP-3 levels. These changes were more pronounced in PCOS patients treated with combined rosiglitazone and clomiphene than in those treated with clomiphene monotherapy. Regular menstrual cycles occurred in 72% of the former group and 48% of the latter.

Conclusion: Combined rosiglitazone and clomiphene was an effective therapeutic regimen for correcting insulin resistance in patients with PCOS, possibly by reducing IGF1 bioavailability to the ovaries, thus modifying the hyperandrogenic intrafollicular milieu that occurs in PCOS. In addition, the clinical and hormonal responses were better than with clomiphene alone.

Keywords

Insulin-like growth factor-1 insulin-like growth factor binding protein-3 polycystic ovary syndrome rosiglitazone clomiphene citrate

Get full access to this article

View all access options for this article.

References

1. Giordano G , Barreca A , Minuto F . Growth factors in the ovary. J Endocrinol Invest 1992;15:689-707.

2. Erickson GF , Magaffin DA , Cragun JR , Chang RJ . The effects of insulin and insulin-like growth factors I and II on estradiol production by granulosa cells of polycystic ovaries. J Clin Endocrinol Metab 1990;70:894-902.

3. Magoffin DA , Weitzman SR . Differentiation of ovarian theca interstitial cells in vitro: Regulation of 17α-hydroxylase messenger ribonucleic acid expression by luteinizing hormone and insulin-like growth factor-1. Endocrinology 1993;132:1945-1951.

4. Morreale HE , Serrano-Gotarredona J , Garcia-Robles R , Varela C , Sancho JM . Abnormalities in the serum insulin-like growth factor-1 axis in women with hyperandrogenism. Fertil Steril 1998;70:1090-1100.

5. Shimasaki S , Ling N . Identification and molecular characterization of insulin-like growth factors binding proteins (IGFBP-1 to 6). Prog Growth Factor Res 1992;3:243-265.

6. Adash EY . Clomiphene citrate-initiated ovulation: A clinical update. Semin Reprod Endocrinol 1986;4:255-255.

7. Kelly JL , Adashi EY . Ovulation induction. Obstet Gynecol Clin North Am 1987;14:831-836.

8. Butzow T , Kettel L , Yen S . Clomiphene citrate reduces insulin-like growth factor-1 and increases sex-hormone binding globulin level in women with polycystic ovary syndrome. Fertil Steril 1995;63:1200-1203.

9. Frank S , Adams J , Mason H , Polson E . Ovulatory disorders in women with polycystic ovary syndrome. Clin Obstet Gynecol 1985;12:605-632.

10.

10. Buttram V , Reiter R . Polycystic ovary syndrome. In: Buttram V , Reiter R , eds. Surgical treatment of infertile women. Baltimore, London: Williams & Wilkins, 1985:229-248.

11.

11. Trott EA , Plouffe L , Hansen K , Hines R , Bran DW , Mahesh VB . Ovulation induction in clomiphene resistant anovulatory women with normal dehydroepiandrosterone sulfate levels: Beneficial effects of the addition of dexamethazone during the follicular phase. Fertil Steril 1996;66:484-486.

12.

12. Porcile A , Gallardo E , Venegas E . Normoprolactinemic anovulation non-responsive to clomiphene citrate: Ovulation induction with bromocriptine. Fertil Steril 1990;53:50-55.

13.

13. Morin-Papunen LC , Koivunen RM , Ruokonen A , Marikainen HK . Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril 1998;69:691-696.

14.

14. Diamanti-Kandarakis E , Kouli C , Tsianateli T , Bergiele A . Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998;138:269-274.

15.

15. Leo VD , Marca AL , Orvieto R , Morgante G . Effect of metformin on insulin-like growth factor (IGF)1 and IGF-binding protein 1 in polycystic ovary syndrome. J Clin Endocrinol Metab 2000;85:1598-1600.

16.

16. Schwartz S , Raskin P , Fonseca V , Graveline JF . Troglitazone and Exogenous Insulin Study Group . Effect of troglitazone in insulintreated patients with type II diabetes mellitus. N Engl J Med 1998;38:861-866.

17.

17. Ehrmann DA , Schneider DJ , Sobel BE . Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2108-2116.

18.

18. Phillips LS , Grunberger G , Miller E , Patwardhan R , Rappaport EB , Salzman A . Rosiglitazone Clinical Trials Study Group . Once and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes Care 2001;24:308-315.

19.

19. Speroff L , Glass RH , Kase NG . Anovulation and polycystic ovary. In: Bill M. Boland , ed. Clinical gynecologic endocrinology and infertility. 5th ed. Baltimore, Maryland: Williams & Wilkins, 1994: Vol. 1. 457-483.

20.

20. Yen S , Laughlin G , Morales A . Interface between extra and intra-ovarian factors in polycystic ovary syndrome (PCOS). Ann N Y Acad Sci 1993;687:98-111.

21.

21. Weissberger A , Ho K , Lazarus L . Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24 hour growth hormone secretion (GH), insulin-like growth factor 1 and GH binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-382.

22.

22. Carmina E , Wong L , Chang L , et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod 1997;12:905-909.

23.

23. Salobir B , Prezelj J , Mendenvrtovee H , Kocijancic A , Osredkar J . Insulin-like growth factor binding protein-3 serum concentrations and ovarian responsiveness in in-vitro fertilization. Hum Reprod 1996;11:2208-2210.

24.

24. Lunenfeld B , Pariente JT , Seppala MT , Mortman H , Insler V . Modern aspects of ovulation induction. Ann N Y Acad Sci 1991;62:207-211.

25.

25. Berg C , Carlsson B , Olsson JH , Selleskog U , Hillensjo T . Regulation of androgen production in cultured human thecal cells by insulin-like growth factor-1 and insulin. Fertil Steril 1993;59:323-331.

26.

26. Suikkari AM , Koivisto VA , Rutanen EM , Yki-Jarvinen H , Karonen SL , Seppala M . Insulin regulates the serum levels of low molecular weight insulin-like growth factor-binding protein. J Clin Endocrinol Metab 1988;66:266-272.

27.

27. Nestler JE , Jakubowicz DJ . Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450C 17a activity and serum androgens. J Clin Endocrinol Metab 1997;82:4075-4079.